Allard NAE, Schirris TJJ, Verheggen RJ, Russel FGM, Rodenburg RJ, Smeitink JAM, Thompson PD, Hopman MTE, Timmers S (2017) Statins affect skeletal muscle performance: evidence for disturbances in energy metabolism. J Clin Endocrinol Metab 103:75–84. https://doi.org/10.1210/jc.2017-01561

Article  Google Scholar 

Armitage J (2007) The safety of statins in clinical practice. Lancet (London, England) 370:1781–1790. https://doi.org/10.1016/S0140-6736(07)60716-8

Article  CAS  PubMed  Google Scholar 

Bakar NSB, Kamali F, Brown CDA (2016) Effect of statins on functional expression of membrane transporters in L6 rat skeletal muscle cells. J Biomed Clin Sci 1:17–26

Google Scholar 

Bell RM, Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway. J Am Coll Cardiol 41:508–515. https://doi.org/10.1016/S0735-1097(02)02816-4

Article  CAS  PubMed  Google Scholar 

Berglund L, Björling E, Oksvold P, Fagerberg L, Asplund A, Al-Khalili Szigyarto C, Persson A, Ottosson J, Wernérus H, Nilsson P, Lundberg E, Sivertsson Å, Navani S, Wester K, Kampf C, Hober S, Pontén F, Uhlén M (2008) A genecentric human protein atlas for expression profiles based on antibodies. Mol Cell Proteom 7:2019–2027. https://doi.org/10.1074/mcp.R800013-MCP200

Article  CAS  Google Scholar 

Björkhem-Bergman L, Lindh JD, Bergman P (2011) What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol 72:164–165. https://doi.org/10.1111/j.1365-2125.2011.03907.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blais JE, Chan EW, Law SWY, Mok MT, Huang D, Wong ICK, Siu C-W (2019) Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015. Atherosclerosis 280:174–182. https://doi.org/10.1016/j.atherosclerosis.2018.11.015

Article  CAS  PubMed  Google Scholar 

Boengler K, Kosiol M, Mayr M, Schulz R, Rohrbach S (2017) Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue. J Cachexia Sarcopenia Muscle 8:349–369. https://doi.org/10.1002/jcsm.12178

Article  PubMed  PubMed Central  Google Scholar 

Bonifacio A, Mullen PJ, Mityko IS, Navegantes LC, Bouitbir J, Krähenbühl S (2016) Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. Arch Toxicol 90:203–215. https://doi.org/10.1007/s00204-014-1378-4

Article  CAS  PubMed  Google Scholar 

Bouitbir J, Charles A-L, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, Piquard F, Geny B, Zoll J (2012) Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a “mitohormesis” mechanism involving reactive oxygen species and PGC-1. Eur Heart J 33:1397–1407. https://doi.org/10.1093/eurheartj/ehr224

Article  CAS  PubMed  Google Scholar 

Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ (2008) Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 23:1182–1186. https://doi.org/10.1007/s11606-008-0636-7

Article  PubMed  PubMed Central  Google Scholar 

Buikema JW, Lee S, Goodyer WR, Maas RG, Chirikian O, Li G, Miao Y, Paige SL, Lee D, Wu H, Paik DT, Rhee S, Tian L, Galdos FX, Puluca N, Beyersdorf B, Hu J, Beck A, Venkamatran S, Swami S, Wijnker P, Schuldt M, Dorsch LM, van Mil A, Red-Horse K, Wu JY, Geisen C, Hesse M, Serpooshan V, Jovinge S, Fleischmann BK, Doevendans PA, van der Velden J, Garcia KC, Wu JC, Sluijter JPG, Wu SM (2020) Wnt activation and reduced cell-cell contact synergistically induce massive expansion of functional human iPSC-derived cardiomyocytes. Cell Stem Cell 27:50-63.e55. https://doi.org/10.1016/j.stem.2020.06.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM (2006) Cell profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7:R100. https://doi.org/10.1186/gb-2006-7-10-r100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England) 380:581–590. https://doi.org/10.1016/S0140-6736(12)60367-5

Article  CAS  Google Scholar 

Cholesterol Treatment Trialists’ C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England) 376:1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5

Article  CAS  Google Scholar 

Cianflone E, Cappetta D, Mancuso T, Sabatino J, Marino F, Scalise M, Albanese M, Salatino A, Parrotta EI, Cuda G, De Angelis A, Berrino L, Rossi F, Nadal-Ginard B, Torella D, Urbanek K (2020) Statins stimulate new myocyte formation after myocardial infarction by activating growth and differentiation of the endogenous cardiac stem cells. Int J Mol Sci 21:7927

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dai D-F, Rabinovitch PS, Ungvari Z, Sinclair D, North B (2012) Mitochondria and cardiovascular aging. Circ Res 110:1109–1124. https://doi.org/10.1161/CIRCRESAHA.111.246140

Article  CAS  PubMed  Google Scholar 

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB (2013) Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 6:400–408. https://doi.org/10.1161/circgenetics.113.000099

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demyanets S, Kaun C, Pfaffenberger S, Hohensinner PJ, Rega G, Pammer J, Maurer G, Huber K, Wojta J (2006) Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochem Pharmacol 71:1324–1330. https://doi.org/10.1016/j.bcp.2006.01.016

Article  CAS  PubMed  Google Scholar 

Du Y, Guo Z (2022) Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discov 8:501. https://doi.org/10.1038/s41420-022-01297-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duan D, Goemans N, Si T, Mercuri E, Aartsma-Rus A (2021) Duchenne muscular dystrophy. Nat Rev Dis Primers 7:13. https://doi.org/10.1038/s41572-021-00248-3

Article  PubMed  PubMed Central  Google Scholar 

Edwards SL, Zlochiver V, Conrad DB, Vaidyanathan R, Valiquette AM, Joshi-Mukherjee R (2018) A multiwell cardiac μGMEA platform for action potential recordings from human iPSC-derived cardiomyocyte constructs. Stem Cell Rep 11:522–536. https://doi.org/10.1016/j.stemcr.2018.06.016

Article  Google Scholar 

Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, Varga ZV, Varró A, Schulz R (2019) Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 40:1771–1777. https://doi.org/10.1093/eurheartj/ehy365

Article  CAS  PubMed  Google Scholar 

Fernández-Vizarra E, Enríquez JA, Pérez-Martos A, Montoya J, Fernández-Silva P (2011) Tissue-specific differences in mitochondrial activity and biogenesis. Mitochondrion 11:207–213. https://doi.org/10.1016/j.mito.2010.09.011

Article  CAS  PubMed  Google Scholar 

Feyen DAM, McKeithan WL, Bruyneel AAN, Spiering S, Hörmann L, Ulmer B, Zhang H, Briganti F, Schweizer M, Hegyi B, Liao Z, Pölönen RP, Ginsburg KS, Lam CK, Serrano R, Wahlquist C, Kreymerman A, Vu M, Amatya PL, Behrens CS, Ranjbarvaziri S, Maas RGC, Greenhaw M, Bernstein D, Wu JC, Bers DM, Eschenhagen T, Metallo CM, Mercola M (2020) Metabolic maturation media improve physiological function of human iPSC-derived cardiomyocytes. Cell Rep 32:107925. https://doi.org/10.1016/j.celrep.2020.107925

Article  CAS  PubMed  Google Scholar 

Godoy JC, Niesman IR, Busija AR, Kassan A, Schilling JM, Schwarz A, Alvarez EA, Dalton ND, Drummond JC, Roth DM, Kararigas G, Patel HH, Zemljic-Harpf AE (2019) Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J 33:1209–1225. https://doi.org/10.1096/fj.201800876R

Article  CAS  PubMed  Google Scholar 

Gu X, Ma Y, Liu Y, Wan Q (2021) Measurement of mitochondrial respiration in adherent cells by Seahorse XF96 Cell Mito Stress Test. STAR Protoc 2:100245. https://doi.org/10.1016/j.xpro.2020.100245

Article  CAS  PubMed  Google Scholar 

Han C, Liu Y, Dai R, Ismail N, Su W, Li B (2020) Ferroptosis and its potential role in human diseases. Front Pharmacol. https://doi.org/10.3389/fphar.2020.00239

Article  PubMed  PubMed Central  Google Scholar 

Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868–873. https://doi.org/10.1161/hc0702.104164

Article  CAS  PubMed  Google Scholar 

Hengstler JG, Sjögren AK, Zink D, Hornberg JJ (2020) In vitro prediction of organ toxicity: the challenges of scaling and secondary mechanisms of toxicity. Arch Toxicol 94:353–356. https://doi.org/10.1007/s00204-020-02669-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hollander JM, Thapa D, Shepherd DL (2014) Physiological and structural differences in spatially distinct subpopulations of cardiac mitochondria: influence of cardiac pathologies. Am J Physiol Heart Circ Physiol 307:H1-14. https://doi.org/10.1152/ajpheart.00747.2013